Table 1 Baseline demographic and clinical characteristics of patients with chemotherapy-induced peripheral neuropathy in the MiroCIP interventional study (full analysis set)
Characteristic | Full analysis set (n = 52)a |
|---|---|
Age, years | 65.5 ± 9.9 |
Sex, male/female | 29 (55.8) / 23 (44.2) |
Body mass index, kg/m2 | 22.50 ± 3.25 |
Creatinine clearance, mL/min | 83.85 ± 26.57 |
Smoking status, current/previous/never | 4 (7.7) / 26 (50.0) / 22 (42.3) |
Alcohol consumption habit | 34 (65.4) |
Cancer type, C / G / N / B | 34 (65.4) / 5 (9.6) / 7 (13.5) / 6 (11.5) |
Cancer stage, II / III / IV / R | 1 (1.9) / 6 (11.5) / 25 (48.1) / 20 (38.5) |
Performance status, 0/1 | 36 (69.2) / 16 (30.8) |
Timing of chemotherapy, post/non-peri | 7 (13.5) / 45 (86.5) |
History of radiotherapy | 6 (11.5) |
Chemotherapeutic agent included in regimen, O/T | 34 (65.4) / 18 (34.6) |
Accumulated dose per body surface area, mg/m2, O/Tb | 1339.52 ± 710.17 / 1310.49 ± 1668.97 |
History of neurotoxic chemotherapy | 17 (32.7) |
 Oxaliplatin | 11 (21.2) |
 Carboplatin | 3 (5.8) |
 Cisplatin | 2 (3.8) |
 Docetaxel | 2 (3.8) |
 Paclitaxel | 2 (3.8) |